Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

ConditionFSHD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Kansas Medical Center

About this trial

The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD.

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Genetically confirmed FSHD (types 1 or 2) or clinical diagnosis of FSHD with characteristic findings on exam and an affected parent or offspring.

Disqualifiers

Unwilling or unable to provide informed consent.

Any other medical condition which in the opinion of the investigator would interfere with study participation.

Trial population

Participants with FSHD that are seen in the researchers clinic. This study is meant to be 'inclusive' and cover the full range of clinical FSHD: including children and adults, all ranges of abilities (ambulatory and non-ambulatory), and both genetic types of FSHD.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

450 Participants
are grouped into 1 trial group
Group A: MOVE FSHD Study Visits

Trial outcomes

Primary outcomes

1

10m walk/run

The 10-meter walk/run (previously the 30 foot go) or gait speed task will be performed during study visits. This task tests a range of different abilities, from power, to endurance, and balance. Also, the 10 meter walk/run is a predictor of loss of ambulation in Duchenne Muscular Dystrophy.

Time frame
Baseline - 5 years
2

Shoulder and Arm Range of Motion

Range of motion tasks mimicking lifting or reaching up will be performed.

Time frame
Baseline - 5 years
3

Shoulder and Arm Function

Participants will be timed on stacking cans.

Time frame
Baseline - 5 years
4

Spirometry (FVC, FEV1, PCF)

Investigators will obtain forced vital capacity and forced expiratory volume in 1 second, both standardized outcomes used commonly in clinic and clinical trials. Also, for sites who routinely collect Peak Cough Flow this will also be obtained.

Time frame
Baseline - 5 years

Secondary outcomes

1

Trunk Function

There are no specific functional tasks designed to measure trunk function in FSHD so Investigators have chosen a practical task that will reflect changes in core truncal muscle groups. The ability to sit up and the timed supine to sitting test reflects core muscle strength and coordination.

Time frame
Baseline - 5 years
2

Hand Function

Hand function is captured by examining hand grip strength.

Time frame
Baseline - 5 years
3

Timed Up and Go (TUG)

Balance and mobility are assessed by using the Timed Up and Go (TUG), a standard outcome measure for the elderly that is also increasingly being used in neuromuscular disorders. Participants are asked to rise from a chair, walk 3 meters, turn 180 degrees and return to a seated position in the chair.

Time frame
Baseline - 5 years
4

Saliva Methylation

Investigators will isolate DNA from blood cells in saliva - and will determine the methylation levels in the 4q region on chromosome 4 using this new technique. Investigators will compare methylation levels between participants and compare to other clinical information collected in this study.

Time frame
Baseline (collected only once)

Other outcomes

1

Biospecimen Retention: Samples with DNA, RNA, plasma, and serum

Optional sub-study collecting DNA, RNA, plasma, and serum for biobanking.

Time frame
Baseline - 5 years
2

Remote Assessment Pilot

A sub-group of approximately 20 participants will perform remote assessments in the home. The remote assessments are meant to capture the assessments that occur during a routine in-person visit, and will overlap functional categories, to include reaching and lifting objects, core functional measures, measures of gait and balance, and midarm and hand tasks. Measures of respiratory (FVC, FEV1, PCF, SNIP), bulbar function, and handgrip strength will also be included. Functional measures will be modified to allow for independent and/or via two-way video performance.

Time frame
Baseline - 5 years
3

MRI

Whole body MRI will be performed for a sub-group of approximately 200 participants. MRI is recognized as a gold standard for body composition analysis, enabling a more complete description of a person's body composition profile from a single examination.In addition, we will include analysis to help make needle biopsy based on STIR and quantitative fat fraction more efficient with higher yield using standard fiducial markings and body landmarks.

Time frame
Baseline - 12-Month
4

Muscle Biopsy

Muscle biopsy will be performed for a sub-group of approximately 200 participants. Muscle biopsies will be performed at the baseline visit and for a subset of 20 participants at 4 months. We will use MRI analysis to help inform which lower extremity muscle will be chosen for biopsy. Muscle samples will be used to recapitulate RNA sequencing to confirm prior DUX4 target selection. In addition, other early or late genes of interest may be included which are FSHD-related but not specific to DUX4. We will also select 4 control genes for quality assurance, 2 to confirm muscle tissue, and 2 to rule out high fat content.

Time frame
Baseline - 4-Month

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Kansas Medical Center

Lead sponsor

FSHD Society, Inc.

Collaborator

Friends Research Institute, Inc.

Collaborator

University of Rochester

Collaborator

University of Nevada, Reno

Collaborator

FSHD Canada

Collaborator

Avidity Biosciences, Inc.

Collaborator

AMRA Medical

Collaborator

Seattle Children's Hospital

Collaborator

Dyne Therapeutics

Collaborator

Hoffmann-La Roche

Collaborator

Springbok Analytics

Collaborator

Novartis Pharmaceuticals

Collaborator